Hyperactivation of peroxisome proliferator-activatedreceptor γ-mediatedtranscription promotes tumor growth in urothelial (bladder) cancer,which can be inhibited by compounds that repress PPARγ activity.FX-909 is a covalent PPARγ inverse agonist in phase 1 clinicaltrials for advanced solid malignancies, including muscle-invasivebladder cancer. The gene discussed is PPARG; the disease is bladder transitional cell carcinoma.